Targeting T regulatory cells in cancer immunotherapy with anti-CD73

Aliyah Weinstein, Ph.D.

In the era of immunotherapy, a major focus of the field is to identify new targets that may improve the immune response to solid tumors. Recently, CD73 has been identified as a novel target for cancer immunotherapy. CD73, also known as ecto-5’-nucleotidase, is an enzyme that is involved in purinergic signaling.1 CD73 is part of a conserved pathway in immune cells that begins with the activity of CD39 (also known as ENTPD1). Together, CD39 and CD73 are responsible for the breakdown of purines by immune cells. CD39 catalyzes the breakdown of ATP and ADP into AMP, and CD73 then converts AMP to adenosine. CD73 is the only known enzyme to have this function.2 Both CD39 and CD73 are located at the cell surface and exert their enzymatic functions on extracellular adenosines.3

In the era of immunotherapy, a major focus of the field is to identify new targets that may improve the immune response to solid tumors. Recently, CD73 has been identified as a novel target for cancer immunotherapy. CD73, also known as ecto-5’-nucleotidase, is an enzyme that is involved in purinergic signaling.1 CD73 is part of a conserved pathway in immune cells that begins with the activity of CD39 (also known as ENTPD1). Together, CD39 and CD73 are responsible for the breakdown of purines by immune cells. CD39 catalyzes the breakdown of ATP and ADP into AMP, and CD73 then converts AMP to adenosine. CD73 is the only known enzyme to have this function.2 Both CD39 and CD73 are located at the cell surface and exert their enzymatic functions on extracellular adenosines.3

Co-expression of CD39 and CD73 defines a specific subset of regulatory T cells (Treg), which are CD4+ CD25+ FoxP3+.4 CD73 is also expressed by CD25- so-called "precursor" helper T cells that do not have suppressive function.5 While the expression of CD73 is limited to just these two subsets of T cells, the suppressive effect of the adenosine produced by the Tregs is broadly acting. Naïve and activated CD4+ Th1 and Th2 cells and cytotoxic CD8+ T cells can all be suppressed by adenosine. Adenosine can bind to the A2a adenosine receptor (A2AR) on the surface of CD4+ and CD8+ effector T cells, and this inhibits cytokine production and proliferation by the effector T cells. Simultaneously, checkpoint blockade molecules including CTLA-4 and PD-1 are upregulated on the surface of the effector T cells.3 The cytolytic function of NK cells is also inhibited by A2AR signaling.6

In the tumor microenvironment, CD73 creates an immunosuppressive niche through the local production of adenosine. In a mouse model, the deletion of A2AR allowed for the rejection of immunogenic tumors, and antagonism of A2AR enhances the efficacy of adoptively transferred anti-tumor CD8+ T cells.7 In a study of human ovarian cancer samples, nearly all samples expressed CD73 and the amount of CD4+ and CD8+ T cell infiltration was correlated with the expression of CD73 by the tumor stroma.8 An anti-CD73 antibody, MEDI9447/oleclumab entered clinical trials for the treatment of advanced colorectal and pancreatic cancers.9 Treatment was shown to decrease the expression of CD73 on peripheral T cells while increasing the amount of CD8+ T cells in the tumor microenvironment. Furthermore, several patients exhibited partial remission or stable disease for 28-322 days. In a later study, combination of an anti-CD73 antibody (BMS0986179) with the anti-PD1 treatment nivolumab in patients with a variety of solid tumors led to 28% of patients exhibiting either a partial response or stable disease.10 In both clinical trials, the anti-CD73 treatments were well-tolerated in comparison to existing immunotherapies. These results demonstrate a need for the continued study of CD73 as an immunotherapeutic target in both preclinical models and clinical trials to further understand the best way to target CD73 in solid tumors.

Try Bethyl's CD73 Antibody for your research needs.

Detection of human CD73 (red) by immunohistochemistry.

Detection of human CD73 (red) by immunohistochemistry. Sample: FFPE section of human tonsil. Antibody: Rabbit anti-CD73 recombinant monoclonal antibody [BLR054F] (A700-054) used at 1:250. Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Substrate: Opal™. Counterstain: DAPI (blue).

Detection of human CD73 by immunocytochemistry.

Detection of human CD73 by immunocytochemistry. Sample: FFPE section of IMR-90 cells. Antibody: Rabbit anti-CD73 recombinant monoclonal antibody [BLR054F] (A700-054) used at 1:100. Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Substrate: DAB.

Detection of human CD73 by immunohistochemistry.

Detection of human CD73 by immunohistochemistry. Sample: FFPE section of human head and neck squamous cell carcinoma. Antibody: Rabbit anti-CD73 recombinant monoclonal antibody [BLR054F] (A700-054) used at 1:500. Secondary: HRP-conjugated goat anti-rabbit IgG (A120-501P). Substrate: DAB.


References

1. Junger WG (2011) Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol 11:201–12 . doi: 10.1038/nri2938

2. Yegutkin GG (2008) Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade. Biochim Biophys Acta - Mol Cell Res 1783:673–694 . doi: 10.1016/j.bbamcr.2008.01.024

3. Haskó G, Linden J, Cronstein B, Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov 7:759–70 . doi: 10.1038/nrd2638

4. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen J-F, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC (2007) Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 204:1257–65 . doi: 10.1084/jem.20062512

5. Kobie JJ, Shah PR, Yang L, Rebhahn JA, Fowell DJ, Mosmann TR (2006) T Regulatory and Primed Uncommitted CD4 T Cells Express CD73, Which Suppresses Effector CD4 T Cells by Converting 5’-Adenosine Monophosphate to Adenosine. J Immunol 177:6780–6786 . doi: 10.4049/jimmunol.177.10.6780

6. Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, Gorelik E (2005) Gs Protein-Coupled Adenosine Receptor Signaling and Lytic Function of Activated NK Cells. J Immunol 175:4383–4391 . doi: 10.4049/jimmunol.175.7.4383

7. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MKK, Huang X, Caldwell S, Liu K, Smith P, Chen J-F, Jackson EK, Apasov S, Abrams S, Sitkovsky M (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci 103:13132–13137 . doi: 10.1073/pnas.0605251103

8. Häusler SFM, Montalbán del Barrio I, Strohschein J, Anoop Chandran P, Engel JB, Hönig A, Ossadnik M, Horn E, Fischer B, Krockenberger M, Heuer S, Seida AA, Junker M, Kneitz H, Kloor D, Klotz K-N, Dietl J, Wischhusen J (2011) Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity. Cancer Immunol Immunother 60:1405–1418 . doi: 10.1007/s00262-011-1040-4

9. Overman MJ, LoRusso P, Strickler JH, Patel SP, Clarke SJ, Noonan AM, Prasanna T, Amin MA, Nemunaitis JJ, Desai J, O’Byrne KJ, George TJ, Englert J, She D, Cooper ZA, Wu Y, Khan A, Kumar R, Bendell JC (2018) Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc). J Clin Oncol 36:4123–4123 . doi: 10.1200/JCO.2018.36.15_suppl.4123

10. Siu LL, Burris H, Le DT, Hollebecque A, Steeghs N, Delord J-P, Hilton J, Barnhart B, Sega E, Sanghavi K, Klippel A, Hedvat C, Hilt E, Donovan M, Gipson A, Basciano P, Postelnek J, Zhao Y, Perez RP, Carvajal RD (2018) Abstract CT180: Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors. In: Clinical Trials. American Association for Cancer Research, pp CT180-CT180